Cargando…
Neuroleptic Malignant Syndrome Associated with Valproate in an Adolescent
Neuroleptic malignant syndrome (NMS) is a life-threatening idiosyncratic reaction that usually occurs after the administration of antipsychotic drugs. Antidepressants, benzodiazepines, and antiepileptic drugs are also suggested to be associated with NMS. It is believed to result from a dopaminergic...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean College of Neuropsychopharmacology
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5290716/ https://www.ncbi.nlm.nih.gov/pubmed/28138117 http://dx.doi.org/10.9758/cpn.2017.15.1.76 |
_version_ | 1782504690694488064 |
---|---|
author | Yıldırım, Veli Direk, Meltem Çobanogulları Güneş, Serkan Okuyaz, Çetin Toros, Fevziye |
author_facet | Yıldırım, Veli Direk, Meltem Çobanogulları Güneş, Serkan Okuyaz, Çetin Toros, Fevziye |
author_sort | Yıldırım, Veli |
collection | PubMed |
description | Neuroleptic malignant syndrome (NMS) is a life-threatening idiosyncratic reaction that usually occurs after the administration of antipsychotic drugs. Antidepressants, benzodiazepines, and antiepileptic drugs are also suggested to be associated with NMS. It is believed to result from a dopaminergic blockade in the central nervous system. NMS is manifested by hyperthermia, muscle rigidity, autonomic dysfunction, altered mental status, leukocytosis, and elevated serum creatinine phosphokinase. Valproate is commonly used in the treatment of many psychiatric and neurologic disorders. Valproate can precipitate NMS, especially when used with antipsychotic drugs concurrently. A 17-year-old male patient, who presented with fever, muscular rigidity, confusion, sweating, and tachycardia was admitted to the emergency room. He had been taking only valproate for the last two months for bipolar disorder. His laboratory analyses revealed raised serum hepatic enzymes, creatinine phosphokinase, and myoglobin levels. Considering fever, rigidity, autonomic dysfunction, cognitive alteration, and high creatinine phosphokinase levels, the patient was diagnosed with NMS. In this paper, we aim to discuss the association between valproate and NMS. |
format | Online Article Text |
id | pubmed-5290716 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Korean College of Neuropsychopharmacology |
record_format | MEDLINE/PubMed |
spelling | pubmed-52907162017-02-06 Neuroleptic Malignant Syndrome Associated with Valproate in an Adolescent Yıldırım, Veli Direk, Meltem Çobanogulları Güneş, Serkan Okuyaz, Çetin Toros, Fevziye Clin Psychopharmacol Neurosci Case Report Neuroleptic malignant syndrome (NMS) is a life-threatening idiosyncratic reaction that usually occurs after the administration of antipsychotic drugs. Antidepressants, benzodiazepines, and antiepileptic drugs are also suggested to be associated with NMS. It is believed to result from a dopaminergic blockade in the central nervous system. NMS is manifested by hyperthermia, muscle rigidity, autonomic dysfunction, altered mental status, leukocytosis, and elevated serum creatinine phosphokinase. Valproate is commonly used in the treatment of many psychiatric and neurologic disorders. Valproate can precipitate NMS, especially when used with antipsychotic drugs concurrently. A 17-year-old male patient, who presented with fever, muscular rigidity, confusion, sweating, and tachycardia was admitted to the emergency room. He had been taking only valproate for the last two months for bipolar disorder. His laboratory analyses revealed raised serum hepatic enzymes, creatinine phosphokinase, and myoglobin levels. Considering fever, rigidity, autonomic dysfunction, cognitive alteration, and high creatinine phosphokinase levels, the patient was diagnosed with NMS. In this paper, we aim to discuss the association between valproate and NMS. Korean College of Neuropsychopharmacology 2017-02 2017-02-28 /pmc/articles/PMC5290716/ /pubmed/28138117 http://dx.doi.org/10.9758/cpn.2017.15.1.76 Text en Copyright © 2017, Korean College of Neuropsychopharmacology This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Yıldırım, Veli Direk, Meltem Çobanogulları Güneş, Serkan Okuyaz, Çetin Toros, Fevziye Neuroleptic Malignant Syndrome Associated with Valproate in an Adolescent |
title | Neuroleptic Malignant Syndrome Associated with Valproate in an Adolescent |
title_full | Neuroleptic Malignant Syndrome Associated with Valproate in an Adolescent |
title_fullStr | Neuroleptic Malignant Syndrome Associated with Valproate in an Adolescent |
title_full_unstemmed | Neuroleptic Malignant Syndrome Associated with Valproate in an Adolescent |
title_short | Neuroleptic Malignant Syndrome Associated with Valproate in an Adolescent |
title_sort | neuroleptic malignant syndrome associated with valproate in an adolescent |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5290716/ https://www.ncbi.nlm.nih.gov/pubmed/28138117 http://dx.doi.org/10.9758/cpn.2017.15.1.76 |
work_keys_str_mv | AT yıldırımveli neurolepticmalignantsyndromeassociatedwithvalproateinanadolescent AT direkmeltemcobanogulları neurolepticmalignantsyndromeassociatedwithvalproateinanadolescent AT gunesserkan neurolepticmalignantsyndromeassociatedwithvalproateinanadolescent AT okuyazcetin neurolepticmalignantsyndromeassociatedwithvalproateinanadolescent AT torosfevziye neurolepticmalignantsyndromeassociatedwithvalproateinanadolescent |